Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07507838
EARLY_PHASE1

Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules

Sponsor: Vigonvita Life Sciences

View on ClinicalTrials.gov

Summary

This study is a single-center, randomized, double-blind, placebo-controlled, dose-escalation trial to assess the safety, tolerability, pharmacokinetics (PK) of multiple doses of VV913 in Chinese healthy adult participants.

Official title: Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules in Chinese Healthy Participants

Key Details

Gender

MALE

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2026-04-01

Completion Date

2026-12-31

Last Updated

2026-04-02

Healthy Volunteers

Yes

Interventions

DRUG

VV913 4mg group

6 participants will receive VV913 4mg orally; 2 participants will receive placebo orally.

DRUG

VV913 8mg group

6 participants will receive VV913 8mg orally; 2 participants will receive placebo orally.

DRUG

VV913 15mg group

6 participants will receive VV913 15mg orally; 2 participants will receive placebo orally.